Reynolds, AlisonAlisonReynoldsVentosa, PilarPilarVentosaGranander, JohanJohanGrananderKilty, ClaireClaireKiltyYoung, ElizabethElizabethYoungButler, Clare T.Clare T.ButlerGalvin, OrlaOrlaGalvinMerrigan, StephanieStephanieMerriganSasore, TemitopeTemitopeSasoreFernandez, YolandaYolandaFernandezGilheany, Declan G.Declan G.GilheanyKennedy, BreandánBreandánKennedy2021-11-092021-11-092017-04-01pA2 Online1741-1157http://hdl.handle.net/10197/12596Pharacology 2016, London, United Kingdom, 13-15 December 2016Introduction: Previously, we identified quininib (2-[(E)-2-(quinolin-2-yl)vinyl]phenol), a cysteinyl leukotriene receptor antagonist with anti-angiogenic and anti-permeable activity (1,2). Here, we report a structure activity relationship study to more comprehensively characterise features which confer anti-angiogenic activity.enCysteinyl leukotriene receptor antagonistsAnti-angiogenic activityBlindnessCancerArthritisQuinoline compoundsStructure-activity relationship of a novel family of cysteinyl leukotriene receptor antagonist quinoline compounds with anti-angiogenic activityConference Publication1612020-09-15https://creativecommons.org/licenses/by-nc-nd/3.0/ie/